论文部分内容阅读
目的:探讨米力农在治疗小儿先天性心脏病合并重症肺炎及心力衰竭的临床疗效。方法:选取我院2015年5月—2017年5月收治的76例小儿先天性心脏病合并重症肺炎及心力衰竭患者作为实验对象,随机分成实验组与对照组,各38例,对照组采用心电监护、抗感染等常规治疗,实验组采用米力农治疗,比较分析两组患者治疗总有效率及心功能改善情况。结果:实验组治疗总有效率是92.10%,对照组为60.53%,实验组治疗总有效率明显高于对照组,差异较大有统计学意义;实验组患者的LVEF(左室射血分数)、LVSF(左室短轴缩短率)、LVDD(左室收缩末径)等明显优于对照组,P<0.05。结论:米力农在治疗小儿先天性心脏病合并重症肺炎及心力衰竭方面效果较好,显著提升了治疗总有效率,改善了患者心功能,值得使用与推广。
Objective: To investigate the clinical efficacy of Milrinone in the treatment of congenital heart disease in children with severe pneumonia and heart failure. Methods: A total of 76 children with congenital heart disease complicated with severe pneumonia and heart failure admitted to our hospital from May 2015 to May 2017 were selected as the experimental subjects and randomly divided into experimental group and control group, with 38 cases in each group. The control group was treated with heart Electrical monitoring, anti-infective and other conventional treatment, the experimental group with Milrinone treatment, comparative analysis of the two groups of patients with total effective rate and improvement of cardiac function. Results: The total effective rate was 92.10% in the experimental group and 60.53% in the control group. The total effective rate in the experimental group was significantly higher than that in the control group, the difference was statistically significant. In the experimental group, LVEF (left ventricular ejection fraction) , LVSF (left ventricular fractional shortening), LVDD (left ventricular end systolic diameter) were significantly better than the control group, P <0.05. Conclusion: Milrinone is effective in treating pediatric congenital heart disease complicated with severe pneumonia and heart failure, which significantly improves the total effective rate of treatment and improves the cardiac function of patients. It is worth using and popularizing.